Boron-containing compounds are being studied as potential therapeutic agents. As part of the safety assessment of these therapeutic agents, a battery of genetic toxicology studies was conducted. The battery included a bacterial reverse mutation (Ames) assay, an in vitro
chromosome aberration assay in peripheral human lymphocytes, and an in vivo rat micronucleus study. The following compounds represent some of the
boron-containing compounds that have been advanced to human clinical trials in various therapeutic areas. The borinic
picolinate,
AN0128, is an antibacterial compound with anti-inflammatory activity that has been studied in clinical trials for
acne and the treatment of mild to moderate
atopic dermatitis.
AN2690 (
tavaborole) is a benzoxaborole in Phase 3 clinical trials for the topical treatment of
onychomycosis, a
fungal infection of the toenails and fingernails. Another benzoxaborole derivative,
AN2728, a
phosphodiesterase-4 (
PDE4) inhibitor, is in Phase 2 clinical trials for the treatment of
atopic dermatitis. AN2898, also a
PDE4 inhibitor, has been studied in clinical trials for
atopic dermatitis and
psoriasis. AN3365 is a leucyl-
tRNA synthetase inhibitor that has been in clinical development for the treatment of various
Gram-negative bacterial infections. These five representative compounds were negative in the three genotoxicity assays. Furthermore,
AN2690 has been studied in mouse and rat 2-year bioassays and was not found to have any carcinogenic potential. These results demonstrate that it is possible to design
boron-based therapeutic agents with no genetic toxicology liabilities.